Pregabalin Capsule
Product Images NDC 71610-887

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71610-887). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 300 mg (71610 0887 30)

This is a description of a medication called Pregabalin which comes in a pack of 30 capsules. The National Drug Code (NDC) for this product is 71610-887-30. The text also includes a list of ingredients or instructions related to the medication. No further details are given.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Equation (Pregabain Gault Equation)

This text provides a formula to calculate CLCr (Creatinine Clearance) based on the patient's age, weight, and serum creatinine levels. It also mentions an adjustment factor for female patients. The formula typically helps in estimating renal function.*

FDA Label Image

Fig-01 (Pregabalin Figure 01)

This is a comparison of the percentage of patients showing improvement in pain from baseline after different treatment regimens: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and Placebo. The chart shows varying levels of improvement ranging from less than 20% to 100%.*

FDA Label Image

Fig-02 (Pregabalin Figure 02)

This information presents a comparison of patients' improvement levels when taking Pregabalin 100 mg three times a day versus a placebo. The data shows the percentage of patients who experienced improvement in pain levels from baseline, ranging from below 10% to 100%. The graph visualizes how the efficacy of Pregabalin compares to the placebo in helping patients manage their pain.*

FDA Label Image

Fig-03 (Pregabalin Figure 03)

This text provides data on the percentage of patients who experienced improvement in pain while taking different doses of pregabalin or a placebo. The graph shows the level of improvement relative to the baseline pain level, with the highest improvement seen in patients taking pregabalin 300 mg twice a day.*

FDA Label Image

Fig-04 (Pregabalin Figure 04)

This text describes a clinical study evaluating the effectiveness of different doses of Pregabalin and a placebo on patients. It shows the percentage of patients improved, the level of pain improvement from baseline, and the dosage regimen of Pregabalin being tested.*

FDA Label Image

Fig-05 (Pregabalin Figure 05)

This is a chart displaying the percentage of patients improved with different treatment dosages. It includes Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and Placebo. The chart also shows percentage improvement in pain from baseline ranging from over 10% to over 90%.*

FDA Label Image

Fig-06 (Pregabalin Figure 06)

This dataset likely represents responder rates for different dosages of a medication in a study. The text shows percentages of responders at various dosage levels (50mg/day, 150mg/day, 300mg/day, 600mg/day) compared to a placebo. It indicates statistically significant results at certain dosage levels. The format suggests a comparison between different studies (Study E1, Study E3) and dosing frequencies (BID - twice a day, TID - three times a day).*

FDA Label Image

Fig-07 (Pregabalin Figure 07)

This description includes statistical data related to the significance of different doses on a certain variable. The text reveals p-values associated with various doses, with a note specifying that only significant p-values are displayed. The data is structured in a table format showing different doses in milligrams per day and their respective significance levels. The study likely evaluates the effects of different doses on the variable under analysis, highlighting statistically significant findings.*

FDA Label Image

Fig-09 (Pregabalin Figure 09)

This data displays the percentage of patients who showed improvement in pain levels when taking different doses of Pregabalin compared to a placebo treatment. The chart indicates the varying levels of improvement achieved by patients across different dosage levels of Pregabalin, with the placebo group showing the least improvement. It is structured to show the percentage of patients experiencing improvement in pain compared to their baseline.*

FDA Label Image

Fig-10 (Pregabalin Figure 10)

The text is not readable.*

FDA Label Image

Fig-11 (Pregabalin Figure 11)

This is a chart showing the percentage of subjects improved from baseline to week 12 for Pregabalin and Placebo. The chart displays the percentage in increments from 0 to 100.*

FDA Label Image

Fig-12 (Pregabalin Figure 12)

This text provides information on the percent of subjects improved with Pregabalin compared to Placebo from baseline to week 16 in a BOCF analysis. Improvement percentages are listed at various levels such as above 10%, 20%, 30%, and so on up to over 80%.*

FDA Label Image

Str (Pregabalin Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.